Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours.

Authors:
Li Y; Wei C; Wang W; Li Q; Wang ZC.

Journal:
J Pathol Clin Res

Publication Year: 2022

DOI:
10.1002/cjp2.307

PMCID:
PMC9896160

PMID:
36533776

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Pathol Clin Res

Abbreviation: J Pathol Clin Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pathology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Aberrant PRDM2 methylation as an early event in serrated lesions destined to evolve into microsatel…
van Toledo DE; Bleijenberg AG; Venema A and 8 more (2024) - Transparency Score: 3/6
ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated wit…
Forster-Sack M; Zoche M; Pestalozzi B and 8 more (2024) - Transparency Score: 3/6
Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial data…
Frei AL; McGuigan A; Sinha RR and 24 more (2023) - Transparency Score: 3/6
AI-based intra-tumor heterogeneity score of Ki67 expression as a prognostic marker for early-stage …
Lu W; Lashen AG; Wahab N and 14 more (2023) - Transparency Score: 3/6
Altered cytoplasmic and nuclear ADP-ribosylation levels analyzed with an improved ADP-ribose binder…
Schraml P; Aimi F; Zoche M and 4 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"No conflicts of interest were declared."

Evidence found in paper:

"This work was supported by grants from the National Natural Science Foundation of China (82102344 and 82172228); Shanghai Rising Star Program supported by the Science and Technology Commission of Shanghai Municipality (20QA1405600); the Science and Technology Commission of Shanghai Municipality (19JC1413); the Natural Science Foundation of Shanghai (22ZR1422300); the ‘Chenguang Program’ supported by the Shanghai Education Development Foundation (SHEDF) (19CG18); the Shanghai Municipal Key Clinical Specialty (shslczdzk00901); Innovative Research Team of high‐level local universities in Shanghai (SSMU‐ZDCX20180700)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025